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Epithelial hyperplasia and metaplasia are common features of inflammatory and neoplastic disease, but the 
basis for the altered epithelial phenotype is often uncertain. Here we show that long-term ciliated cell hyper-
plasia coincides with mucous (goblet) cell metaplasia after respiratory viral clearance in mouse airways. This 
chronic switch in epithelial behavior exhibits genetic susceptibility and depends on persistent activation of 
EGFR signaling to PI3K that prevents apoptosis of ciliated cells and on IL-13 signaling that promotes transdif-
ferentiation of ciliated to goblet cells. Thus, EGFR blockade (using an irreversible EGFR kinase inhibitor des-
ignated EKB-569) prevents virus-induced increases in ciliated and goblet cells whereas IL-13 blockade (using 
s-IL-13Rα2-Fc) exacerbates ciliated cell hyperplasia but still inhibits goblet cell metaplasia. The distinct effects 
of EGFR and IL-13 inhibitors after viral reprogramming suggest that these combined therapeutic strategies 
may also correct epithelial architecture in the setting of airway inflammatory disorders characterized by a 
similar pattern of chronic EGFR activation, IL-13 expression, and ciliated-to-goblet cell metaplasia.
*OUSPEVDUJPO
Epithelial cell hyperplasia and metaplasia are common conse-
quences of inflammation and may be associated with protective 
as well as pathogenic outcomes. In the lung, airway epithelial 
remodeling can be life threatening, since mucous cell metaplasia 
is the foundation for hypersecretion that can obstruct the airway 
lumen. Despite the critical nature of this process, little is known 
about how mucous cell metaplasia develops in the setting of acute 
or chronic inflammatory disease. Particularly, little is known 
about the mechanism for what is likely the most common cause 
of mucous cell metaplasia in the lung, i.e., respiratory viral infec-
tion, since previous work has focused on bacterial, allergic, and 
carcinogenic stimuli. Perhaps because of the paucity of mechanis-
tic information, no effective and specific pharmacologic treatment 
is currently available to treat epithelial cell metaplasia in general or 
mucous cell metaplasia in particular.
In this context, recent work on mucous cell metaplasia has often 
focused on signaling pathways initiated by activation of the IL-13 
receptor (IL-13R) and EGFR (also designated ErbB1 and HER1). 
The experimental role of IL-13R was established when a decoy 
receptor for IL-13 (soluble IL-13Rα2-Fc) was found to inhibit aller-
gen-induced mucous (goblet) cell formation in mice (1, 2). These 
reports have been followed by evidence that IL-13 can directly drive 
mucin gene expression in airway epithelial cells cultured under 
physiologic conditions and in vivo (3–6). Moreover, IL-13 is often 
overexpressed in the setting of mucous cell metaplasia in asthma 
and chronic obstructive pulmonary disease (COPD) (7–9). The 
downstream events connecting IL-13R activation to mucin gene 
expression are incompletely defined, but preliminary work with 
inhibitors indicates requirements for MEK/ERK, p38 MAPK, and 
PI3K activation, at least in vitro (5). These effects appear to develop 
in concert with calcium-activated chloride conductance to promote 
fluid secretion and consequent mucociliary clearance (10). This 
function may be connected to expression of a calcium-activated 
chloride channel (CLCA) that is specific for goblet cells (11). Thus, 
IL-13 appears to directly stimulate epithelial mucin formation, but 
the type of epithelial cell that is targeted and the cellular process for 
mucous cell differentiation remain less certain.
Similar to the case for IL-13, the pathway for EGFR activa-
tion leading to mucous cell metaplasia is not well defined. First, 
altered EGFR expression has been found in humans with asthma 
(known to exhibit goblet cell metaplasia) and in animal models of 
asthma, but expression has been variably found on goblet cells as 
well as other types of airway epithelial cells, e.g., squamous, basal, 
ciliated, and Clara cells (12–21). This variability is further compli-
cated by uncertainty over the specificity of anti-EGFR antibodies 
and their capacity to define EGFR activation status. Second, simi-
lar to the case for IL-13, animal models often rely on allergen chal-
lenge that appears to drive mucin gene expression predominantly 
in cells that resemble Clara cells by morphology (22–24). These 
cells express Clara cell secretory protein (CCSP), but tracking cell 
lineage is complicated by EGFR and IL-13–dependent stimulation 
of CCSP expression, perhaps in multiple cell types (25). Third, 
extensions of these studies to signaling mechanisms have often 
been performed in transformed cell lines (17, 19, 26–31), and even 
when primary airway epithelial cells were used, cultures were not 
fully differentiated under physiologic conditions to a respiratory 
epithelium (18, 32–34). Thus, 1 biochemical scheme from this 
work suggests that IL-13 stimulation of EGFR signaling leads to 
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mucin gene expression (21), but studies of airway epithelial cells 
under physiologic conditions show that IL-13 fully stimulates 
goblet cell metaplasia despite EGFR blockade (5). Thus, there is 
likely a fundamental requirement for EGFR activation in muco-
ciliary differentiation (5, 35), but how this requirement may be 
linked to the modification of epithelial cell growth or differen-
tiation during cytokine stimulation, inflammation, and/or infec-
tion still needed to be defined. Fourth, the whole subject of EGFR 
regulation of cell survival, which appears so critical for neoplasia, 
has not yet been taken into account in the process of epithelial 
cell metaplasia during inflammatory disease. Finally, previous 
approaches concentrate predominantly on the acute phase of epi-
thelial remodeling without addressing chronic goblet cell meta-
plasia that may be found in hypersecretory airway diseases 
such as asthma and COPD.
To address these issues, we studied a mouse model of air-
way epithelial remodeling that is inducible by viral infection 
and features a delayed but permanent switch to goblet cell 
metaplasia (36). The observed patterns of acute infection 
and chronic remodeling were characterized in detail, in par-
ticular the dissociation between the acute antiviral response 
that allows for viral clearance versus the subsequent post-
viral response manifested by chronic airway hyperreactivity 
and goblet cell metaplasia (36, 37). When we examined the 
behavior of EGFR signaling in this model, we detected acute 
activation of EGFR during the epithelial repair phase that 
was replaced by chronic activation of EGFR localized to cili-
ated epithelial cells. This chronic activation coincides with 
ciliated cell hyperplasia without a requirement for ongo-
ing epithelial proliferation. Both ciliated cell hyperplasia 
and goblet cell metaplasia could be prevented by treatment 
with a new irreversible inhibitor of EGFR tyrosine kinase. 
These findings suggested a role for EGFR-dependent signal-
ing pathways in ciliated cell survival, and we subsequently 
detected and defined such a mechanism that proceeds via 
PI3K/Akt signaling to selectively protect ciliated epithelial 
cells from apoptosis. However, this mechanism did not read-
ily explain a requirement for EGFR signaling in goblet cell 
metaplasia until we next detected ciliated cells that appeared 
to transdifferentiate to goblet cells under pressure from IL-13 
stimulation. Thus, in vivo inhibition of IL-13 signaling 
blocks goblet cell formation but also, by preventing trans-
differentiation, further increases the level of ciliated cell 
hyperplasia. The results thereby provide a new paradigm 
for chronic goblet cell metaplasia that depends on persis-
tent activation of 2 complementary pathways: EGFR-PI3K 
signals that protect against ciliated cell apoptosis and IL-13 
signals that promote ciliated to goblet cell transdifferentia-
tion. This scheme is consistent with EGFR and IL-13 effects 
on epithelial cells as well as evidence of ciliated cell EGFR 
activation, IL-13 production, and goblet cell metaplasia 
in the epithelium of asthmatic subjects. Therefore, treat-
ment to fully restore normal epithelial behavior in asthma 
and related hypersecretory conditions such as COPD may 
need to be directed at combined correction of EGFR- and 
IL-13–dependent abnormalities in airway epithelial cell 
survival and differentiation. In that regard, we establish the 
efficacy of an orally active and irreversible EGFR inhibitor 
and a soluble IL-13 decoy to prevent these abnormalities in 
epithelial architecture.
3FTVMUT
Persistent activation of EGFR on ciliated epithelial cells. Common human 
paramyxoviruses often replicate poorly in mice, but mouse parain-
fluenza virus (Sendai virus; SeV) replicates with high efficiency in 
the bronchiolar mucosa, with consequent induction of immune-
response gene expression, immune cell infiltration, and damage of 
the epithelium (37). This host response allows for complete clearance 
of SeV by 10–12 days after inoculation (36, 38). The injury is followed 
by epithelial repair and restoration of normal airway architecture in 
some mouse strains (see below) but can be followed by long-term 
(likely permanent) goblet cell metaplasia in C57BL/6J mice that 
appears at 21 days after inoculation (36). Since EGFR signaling is 
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behavior in mouse airway epithelium in this model. Western blot 
analysis indicated that anti-EGFR and anti–phospho-EGFR (anti– 
p-EGFR) antibodies specifically recognized the receptor in airway tis-
sue samples (data not shown). Immunostaining of airway tissue with 
anti-EGFR antibody indicated that EGFR expression was predomi-
nantly localized to the apical membrane of ciliated epithelial cells, 
although other cell types (e.g., basal cells and airway smooth muscle 
cells) were also weakly immunostained (Figure 1A). No significant 
difference was observed in the pattern or the level of anti-EGFR 
immunostaining between mice infected with SeV and control mice 
that were inoculated with UV-inactivated SeV (SeV-UV). In contrast, 
immunostaining for p-EGFR (using an anti–p-EGFR antibody that 
recognizes phosphorylated Tyr845) indicated that levels of activated 
EGFR were persistently increased at 21 days after inoculation with 
SeV compared with uninoculated or SeV-UV–inoculated control 
mice. Similar to the pattern for EGFR expression, p-EGFR was also 
localized mainly to the apical surface of ciliated epithelial cells, but 
in this case, apical cell staining was also accompanied by correspond-
ing nuclear staining in this same ciliated cell population (Figure 1A). 
Other cell types (e.g., basal cells) were also weakly immunostained in 
nuclear and cytosolic locations. These findings are consistent with 
reports of nuclear translocation of activated EGFR (39). This pat-
tern of immunostaining indicated that the initial EGFR antibody 
recognizes predominantly the unphosphorylated receptor. For both 
antibodies, immunostaining was completely abolished by preabsorp-
tion with corresponding antigen. In addition, normal rabbit IgG was 
used as a negative isotype control and showed no significant signal 
above background. In further support of EGFR expression local-
ized predominantly to ciliated epithelial cells, double labeling and 
immunofluorescence detected by laser scanning confocal microscopy 
indicated that EGFR colocalized with a marker for ciliated epithelial 
cells (i.e., β-tubulin) but not with markers for Clara cells (i.e., CCSP) 
or goblet cells (i.e., MUC5AC) in mouse airways (Figure 1B).
This pattern of EGFR immunostaining found in mice was simi-
lar to the one in human subjects. In particular, EGFR expression 
was also localized to the apical cell membrane of ciliated epithelial 
cells in normal and asthmatic subjects, and p-EGFR was increased 
in asthmatic subjects that also manifested goblet cell metaplasia 
(Supplemental Figure 1; supplemental material available online 
with this article; doi:10.1172/JCI25167DS1). Expression of p-EGFR 
was similarly localized to the apical portion of ciliated epithelial 
cells, and expression was accompanied by corresponding nuclear 
staining in the same ciliated cells. Additional, albeit weaker, p-EGFR 
immunostaining was also present on basal cells in both normal and 
asthmatic subjects. This finding was also consistent with previous 
reports of EGFR expression in this basal cell population (12, 15, 
18, 19). The present pattern of EGFR localization to the apical and 
ciliary regions of ciliated epithelial cells is consistent with obser-
vations in developing lung and other sites (40–43). Others report 
basolateral localization of EGFR in some epithelial tissues (e.g., gut 
and kidney) (44, 45) and in airways (46); we find expression at this 
location as well but without any predilection for ciliated cells. In 
either case, the consistent finding of EGFR and p-EGFR expression 
on ciliated epithelial cells in mouse and human airways led us to 
continue these studies in a mouse model of asthma, where experi-
mental conditions and genetic background are more completely 
controlled and more extensive lung sampling is possible.
EGFR as a critical component in epithelial remodeling. To define a func-
tional role for persistent EGFR signaling on ciliated epithelial cells, 
lung sections were subjected to immunostaining with markers for 
ciliated epithelial cells, Clara cells, and goblet cells. Quantitative anal-
ysis of cell types found in the airway epithelium indicated that SeV-
infected mice developed increases in ciliated and goblet cells and con-
comitant decreases in Clara cells at day 21 (but not by day 12) after 
inoculation compared with control mice inoculated with SeV-UV 
(Figure 2). We next determined whether EGFR signaling was neces-
sary for these observed changes in epithelial architecture. For these 
studies, we used a new irreversible EGFR inhibitor (EKB-569) that 
selectively inhibits EGFR signaling in airway epithelial cells in vitro 
(Supplemental Figure 2). To achieve blockade in vivo, we adminis-
tered EKB-569 orally each day from postinoculation day 10 (so as not 
to interfere with viral clearance or epithelial repair) through day 21 
(when the remodeling response developed). Under these treatment 
conditions, EKB-569 also blocked EGFR signaling in vivo (Supple-
mental Figure 2). Moreover, when provided in this way, EGFR 
inhibitor treatment also helped to correct all 3 aspects of epithelial 
remodeling. Specifically, we observed complete blockade of ciliated 
cell increases and Clara cell decreases and partial but significant inhi-
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no effect on the total number of airway epithelial cells (cytokeratin-
staining cells were 133 ± 3 after vehicle and 137 ± 5/mm basement 
membrane after drug treatment on postinoculation day 21), consis-
tent with compensatory changes in other epithelial cell (e.g., basal 
and Clara cell) populations. Based on immunohistochemical data 
showing localization of EGFR and β-tubulin expression together 
in the same ciliated cell population, we expected that EGFR block-
ade might influence ciliated cell hyperplasia. However, the effect of 
interrupting EGFR signals on goblet cell (or Clara cell) levels was 
unexpected based on the relative absence of activated EGFR expres-
sion on either of these cell types. Further experiments were therefore 
designed to better understand the mechanisms underlying the role 
of EGFR in chronic epithelial remodeling.
We reasoned that epithelial hyperplasia could either be a result 
of increased proliferation or decreased cell death. We therefore ini-
tially looked for evidence of increased proliferation in mice with 
epithelial remodeling. As noted previously, there was transient epi-
thelial proliferation (marked by BrdU labeling) during days 5–12 
after infection (Figure 3, A and B, and ref. 47). The same pattern of 
immunostaining was found for Ki-67 and proliferating cell nuclear 
antigen (PCNA) proliferation markers (data not shown). This pro-
liferative response likely allows for replacement of host cells that 
suffer direct cytopathic effects and immune-mediated cell death in 
the wake of viral replication (38). Not surprisingly, this repair phase 
is accompanied by EGFR activation in epithelial cells (generally 
basal cells) as well as subepithelial (likely immune) cells (Figure 3C). 
However, by postinoculation day 21, there was no longer evidence 
of an ongoing proliferative response, since cellular proliferation 
was no different than in noninoculated control mice (Figure 3, 
A and B). Moreover, this replacement phase (marked by BrdU uptake 
and EGFR activation in the basal cell compartment) was the same 
in a strain of mice (Balb/cJ) that does not develop long-term epi-
thelial remodeling (Figure 3, A–E). Thus, this transient proliferative 
response could not account for the subsequent long-term remod-
eling that was found only in genetically susceptible (C57BL/6J) 
mice. Moreover, the lack of an ongoing epithelial proliferative 
response suggested that ciliated cell hyperplasia might reflect a 
selective increase in EGFR-dependent cell survival based on sup-
pression of cell death in this subpopulation of epithelial cells.
EGFR signaling and ciliated cell survival in culture. To determine 
whether EGFR provides necessary survival signals to ciliated epi-
thelial cells, we next analyzed EGFR blockade in tissue culture 
where macrophage clearance would not obscure detection of apop-
totic cells and where signaling events could be better defined. Initial 
experiments aimed to determine whether EGFR was localized to 
ciliated epithelial cells in culture as was found in vivo. We therefore 
reconstituted the epithelial system in vitro using air-liquid interface 
cultures of airway epithelial cells harvested from mouse trachea. In 
this system, ciliated (β-tubulin–positive) cells represented 45% ± 1% 
of the total cell population, a level that was similar to normal mouse 
airways (36% for large-sized airways) and to values for mouse tra-
cheal specimens reported previously (48). As was the case in vivo, 
the ciliated epithelial cells in culture exhibited constitutive expres-
sion of EGFR and p-EGFR along the apical cell membrane; p-EGFR 
was found in this location as well as a nuclear one following activa-
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that EGFR may also be localized to the basolateral cell membrane 
in cultured airway epithelial cells (46), but any differences could 
depend on culture conditions, receptor heterogeneity that influ-
ences recognition by different antibodies, or receptor abundance 
that may influence apical versus basolateral localization (49).
We next defined the role of EGFR signaling in ciliated epithelial 
cell growth and survival using treatment with selective inhibitors. 
Initial experiments to validate inhibitor specificity used cultures 
that were first removed from complete medium and then stimu-
lated with EGF to maximize EGFR-dependent signals. Under these 
conditions, we found that EGFR tyrosine kinase inhibition with 
PD153035 blocked all downstream signals, while PI3K inhibition 
with LY294002 blocked phosphorylation of Akt, and MEK1/2 inhibi-
tion with PD98059 blocked phosphorylation of ERK1/2 (Figure 4B). 
The next experiments determined the effect of these EGFR signals 
on ciliated cell survival. We found that treatment with PD153035 
caused a dose-dependent loss of ciliated cells out of proportion to 
the consequent decrease in total epithelial cells (Figure 4C). Similar 
results were obtained with another EGFR-specific inhibitor, AG1478 
(data not shown). Recognizing that EGFR activation triggers several 
downstream signaling pathways, we next treated mouse tracheal epi-
thelial cell (mTEC) cultures with inhibitors of PI3K and MEK1/2 and 
found that only treatment with LY294002 caused a similar loss of 
ciliated epithelial cells (Figure 4D). Since this culture system does not 
exhibit significant cell growth at high density, it appeared likely that 
the loss of ciliated epithelial cells was due to decreased cell survival.
Accordingly, we next tested whether blockade of EGFR signaling 
led to concordant changes in the level of apoptosis. In parallel with 
loss of ciliated epithelial cells, we also observed rapid activation of 
caspase-3 and TUNEL-positive cells (within 6 hours) in the same 
pattern that we had observed for cell loss, i.e., when EGFR or PI3K 
but not MEK1/2 signaling was blocked (Figure 5A). In this setting, 
TUNEL-positive cells were undergoing apoptosis, since this process 
was blocked by treatment with the caspase-inhibitor z-Val-Ala-Asp 
fluoromethylketone (z-VAD-fmk) (Figure 5B) and was associated 
with caspase-3 and caspase-9 cleavage/activation (Figure 5C) and 
loss of mitochondrial membrane potential (Figure 4D). These results 
therefore define an EGFR signaling pathway that protects against 
ciliated cell apoptosis via selective PI3K signaling to downstream fac-
tors that prohibit mitochondrial dysfunction and consequent pro-
grammed cell death. As discussed below, the findings stand in some 
contrast to reports of EGFR and other receptor signals to ERK1/2 
that prevent cell death under other circumstances (38, 50, 51).
EGFR signaling and goblet cell metaplasia in vitro and in vivo. As noted 
above, the actions of EGFR signaling on ciliated cells did not read-
ily explain the effect of EGFR blockade on goblet cell metaplasia in 
vivo. In particular, selective EGFR expression and consequent sur-
vival function on ciliated cells could account for inhibition of cili-
ated cell hyperplasia but could not account directly for blockade of 
goblet cell metaplasia as well. Despite the low levels of EGFR expres-
sion on goblet cells, we next questioned whether EGFR might still 
have a similar functional effect on goblet cell survival. To test this 
possibility, we took advantage of concomitant studies that defined 
IL-13 dependence of goblet cell metaplasia after viral infection (E.Y. 
Kim and M.J. Holtzman, unpublished observations). This effector 
pathway therefore overlaps with that established in studies of mucin 
production after allergen challenge (1, 2). In addition, we recognized 
the capacity of IL-13 treatment to stimulate goblet cell formation in 
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airway epithelial cells cultured from guinea pigs and humans (3–5) as 
well as mice (J.D. Morton and M.J. Holtzman, unpublished observa-
tions). Cultured mTECs were therefore treated with IL-13, and the 
subsequent development of goblet cells was marked by expression of 
MUC5AC. Cell death was tracked with activation of caspase-3, since 
the procedure for the TUNEL reaction appears to decrease mucin 
content. In contrast to ciliated cells, we found that goblet cells did 
not exhibit increased rates of cell death in response to EGFR inhi-
bition (Figure 6A). Quantifying the level of active caspase-3 cells in 
MUC5AC-positive versus MUC5AC-negative populations indicated 
that the level of apoptosis was similar in goblet cells with or without 
EGFR blockade, whereas the nongoblet cells (i.e., ciliated epithelial 
cells) exhibited significant caspase-positive staining under these 
treatment conditions (Figure 6B). Moreover, the level of nongoblet 
cell death was similar with or without IL-13 treatment, indicating 
that the death pathway in ciliated cells is not influenced by IL-13–
dependent actions on goblet cell formation.
Since EGFR blockade caused no effect on goblet cell survival 
in vitro, we reasoned that the potent effects of EGFR blockade 
on goblet cell metaplasia in vivo might be downstream of EGFR 
blockade of ciliated cell hyperplasia. Support for that possibility 
was obtained when we found that IL-13 treatment led to the devel-
opment of cells that transiently shared characteristics of ciliated 
and goblet cells. Thus, electron microscopy of mTEC cultures pro-
vided evidence of a subset of cilia-goblet cells with preservation of 
cilia and the gradual development of mucous granules under the 
influence of IL-13 (Figure 7). These transitional cells were most 
prominent early (1–2 days) after initiation of IL-13 treatment, 
while mature goblet cells without cilia were most abundant at 
later times (5 days) after treatment. The morphologic characteris-
tics of cilia-goblet cells under these conditions appear quite simi-
lar to ciliated cells containing mucous granules found by electron 
microscopy in airways of allergen-challenged mice (23).
Since airway epithelial cultures were established under conditions 
that required IL-13 treatment to promote goblet cell formation in an 
environment that would otherwise produce ciliated cells, these cilia-
goblet cells were likely being redirected by IL-13 to transdifferentiate 
from a ciliated to goblet cell phenotype. The possibility that simi-
lar transdifferentiation also developed in vivo was next confirmed 
in sections taken from mice exhibiting goblet cell metaplasia after 
inoculation with SeV. Confocal microscopy indicated that, while 
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MUC5AC, respectively, there was a subpopulation of epithelial cells 
that expressed both β-tubulin and MUC5AC (Figure 8A). Similarly, 
confocal images also indicated that, in general, ciliated but not gob-
let cells expressed EGFR, but there was an additional subpopulation 
of cells that expressed both EGFR and MUC5AC (Figure 8B). In each 
case, multiple confocal sections along the z axis and 3D reconstruc-
tion were used to confirm colocalization within a single cell. The 
subpopulation expressing MUC5AC and β-tubulin and or MUC5AC 
and EGFR appeared to be in transition, since they did not often reach 
their characteristic shape and position at the lumenal surface of the 
mucosal epithelial layer as was found for mature goblet cells. In addi-
tion, in these transitioning cells, the mucous granules were often 
localized in a more basal compartment of the cells versus a more 
apical location for fully differentiated goblet cells. This morphologic 
behavior also suggests that these cilia-goblet cells represent goblet 
cell precursors. As noted previously for allergen-induced goblet cell 
metaplasia, we also detected a subpopulation of epithelial cells with 
coexpression of CCSP and MUC5AC (Figure 8C) at levels compa-
rable to detection of cilia-goblet cells (Figure 8E).
We next aimed to establish whether IL-13 also promotes cilia to gob-
let cell formation in vivo as we had observed in vitro. For these experi-
ments, we took advantage of a recombinant soluble IL-13R α2 Fc 
fusion protein (designated sIL-13Rα2-Fc) that acts as a decoy recep-
tor to specifically block IL-13 action when delivered to mice (1, 2). 
Treatment conditions were chosen to be similar to those used for 
EGFR blockade, so treatment extended from day 12 to 21 after viral 
inoculation. This time frame also coincides with the induction of 
IL-13, mCLCA3, and MUC5AC gene expression in concert with the 
development of goblet cell metaplasia (Figure 8D). Under these con-
ditions, we found that sIL-13Rα2-Fc treatment was highly effective 
in preventing virus-induced goblet cell metaplasia (Figure 8E). How-
ever, in some contrast to EGFR blockade, sIL-13Rα2 treatment also 
caused a further increase in the level of ciliated cell hyperplasia (con-
sistent with a block in their movement to goblet cells) and no change 
in Clara cell levels (consistent with the possibility that goblet cell 
formation derives at least in part from ciliated cell rather than Clara 
cell populations). We cannot fully exclude the possibility that other 
cellular sources (e.g., Clara cells or basal cells) may also contribute to 
goblet cell metaplasia in this setting, but the close match of ciliated 
cell increase to goblet cell decrease after IL-13 blockade suggests that 
transdifferentiation of the ciliated cell population is a significant 
pathway for goblet cell metaplasia under these conditions. Indeed, 
together with previous and present evidence of Clara cell expression 
of mucin genes, the present results may simply provide evidence of 
additional plasticity of epithelial cell differentiation.
In a final 2 sets of experiments, we again extended our findings 
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ments, we analyzed airway tissue from a group of COPD patients 
that exhibited markedly increased levels of goblet cells in the airway 
and provided adequate lung tissue for analysis at the time of lung 
transplantation. By applying the same immunostaining protocol 
for immunofluorescence and confocal microscopy as for the mouse 
model, we found that sections of lung explants from COPD patients 
also exhibited evidence of β-tubulin–MUC5AC coexpression in a 
subset of airway epithelial cells (Figure 9A). We did not detect lume-
nal staining for β-tubulin in human (or mouse) airways, consistent 
with the proposal that cilia may be processed by endosomal degrada-
tion rather than shedding. As noted previously (52), CCSP-MUC5AC 
coexpression was also found in a subset of epithelial cells. In the 
second set of experiments, we again applied the strategy that we 
used for mouse studies and analyzed the behavior of human airway 
epithelial cells in air-liquid interface culture conditions without or 
with IL-13. In this case, we found that airway epithelial cells cultured 
from COPD patients led to the development of a subset of cells that 
coexpressed β-tubulin and MUC5AC under the influence of IL-13. 
As noted previously, β-tubulin is localized within the basal bodies 
of ciliated cells (53) and so provides even closer colocalization with 
MUC5AC found in mucous granules. The same pattern of IL-13–
induced coexpression of ciliated and goblet cell markers was found 
in airway epithelial cells cultured from otherwise healthy lung trans-
plant donors in response to IL-13, even within the first day of IL-13 
treatment (Figure 9C). As we did for the studies of mouse and human 
tissue, we examined multiple confocal images along the z axis and 
3D reconstruction to establish colocalization of ciliated and goblet 
cell markers within a single cell. Thus, similar to our experience for 
EGFR activation in human subjects, we found that the downstream 
mechanism for goblet cell metaplasia found in the mouse model, i.e., 
IL-13–driven ciliated-to-goblet cell transdifferentiation, appears to 
have a counterpart in hypersecretory human disease.
%JTDVTTJPO
The present report provides initial evidence that transient viral 
bronchiolitis causes a long-term switch to ciliated cell hyperplasia 
as well as goblet cell metaplasia and that the hyperplastic ciliated 
cell population exhibits persistent EGFR activation without pro-
liferation. This finding came in some contrast to the fate of cili-
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also primarily responsible for airway repair in concert with EGFR 
expression but depends on a marked proliferative response (14, 54). 
The present findings therefore raised the unexpected possibility 
that prolonged EGFR-dependent cell survival (not proliferation) 
is critical for remodeling of epithelial structure toward a chronic 
asthma/bronchitis phenotype. Support for this possibility was 
obtained when we showed that EGFR blockade prevented ciliated 
cell hyperplasia in vivo and caused ciliated epithelial cell apoptosis 
in vitro. Additional study of airway epithelial cells cultured under 
physiologic conditions indicated that ciliated epithelial cell survival 
depends on uninterrupted EGFR signaling to PI3K. Otherwise, the 
ciliated cells proceed toward programmed cell death (via caspase 
activation) in a manner that appears analogous to virus-inducible 
apoptosis (38). The fidelity of the present model to human disease 
is supported by initial experiments that detect ciliated epithelial 
cells with activated EGFR in airway sections from subjects with 
asthma, but further studies will be needed to verify this finding and 
extend it to other chronic airway diseases. Nonetheless, the present 
findings indicate that the plasticity and responsiveness of ciliated 
cells in the setting of airway damage and inflammation is an under-
appreciated but seminal feature of airway epithelial remodeling.
The second major set of findings of the present study was focused 
on IL-13 signaling and the capacity of ciliated cells to transdiffer-
entiate to goblet cells under IL-13 stimulation. This finding was 
also unexpected, since previous work had suggested that IL-13 may 
cause a decrease in ciliated cells and an increase in goblet cells, but 
no apparent connection was drawn between the 2 phenomena (3, 5). 
In the present work, we were able to capture snapshots of epithe-
lial cells in vitro and in vivo that appear to be transitioning from 
a ciliated to a goblet cell phenotype under pressure from IL-13. In 
addition, we detected reciprocal increases in ciliated cell levels dur-
ing IL-13 blockade in vivo. Additional cell lineage studies of this 
process are needed to fully define the mechanism of transdifferen-
tiation, but the evidence points to a program that carefully coordi-
nates ciliated and goblet cell formation to achieve proper mucosal 
immunity. Indeed, epithelial EGFR activation, ciliated cell hyper-
plasia, IL-13 production, and goblet cell metaplasia appear to devel-
op together in time. This type of coordination is likely required for 
efficient mucociliary function. The present results suggest that 
abnormally prolonged IL-13 production may lead to goblet cell 
metaplasia beyond the initial repair phase and so explain how gob-
let cell metaplasia may develop in this setting. Thus, genetic suscep-
tibility to the development of persistent EGFR activation as well as 
IL-13 production after viral infection may allow for the consequent 
development of goblet cell metaplasia. Whether a similar paradigm 
applies to other asthmagenic stimuli (e.g., allergen exposure) will 
need further study in models that mimic the human condition. 
Nonetheless, the fidelity of the present model to human disease is 
again supported by initial experiments that detect ciliated-to-goblet 
cell transdifferentiation in airway sections and cultured cells from 
patients with COPD likely under the influence of IL-13.
Together, our results on EGFR- and IL-13–dependent signaling 
provide a new paradigm for epithelial host defense and remodeling 
(summarized in Figure 10) that should be useful for developing a 
rational basis for therapies aimed at downregulating hypersecretory 
conditions. Thus, tyrosine kinase inhibitors in general and EGFR 
tyrosine kinase inhibitors in particular are being broadly developed 
for use in conditions exhibiting abnormal epithelial architecture, 
including asthma and COPD, but the cellular signaling context 
for their application to airway disease was uncertain. The present 
strategy utilized an irreversible inhibitor of EGFR tyrosine kinase 
activity that showed efficacy in preventing epithelial hyperplasia in 
a model of intestinal neoplasia (55). In that setting, the pharmaco-
logic strategy was aimed at inhibiting epithelial proliferation, but 
our findings indicate that interrupting antiapoptotic signals may be 
the primary target in inflammatory airway disease. Further develop-
ment of approaches for targeting EGFR (as well as those directed 





































Downloaded on July 24, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/25167
SFTFBSDIBSUJDMF
 The Journal of Clinical Investigation   http://www.jci.org   Volume 116   Number 2   February 2006
the signaling events that regulate airway epithelial cell apoptosis 
and transdifferentiation. In that regard, we provide evidence that 
downstream signaling to prevent epithelial cell apoptosis proceeds 
through EGFR-dependent PI3K but not MEK/ERK activation based 
on selective inhibition. This finding implies that the targeted path-
way extends from EGFR homo- or heterodimerization and activation 
of the receptor tyrosine kinase cytosolic domain to autophosphory-
lation of tyrosine resides within the cytoplasmic domain, docking of 
Gab2/PI3K, and subsequent activation of Akt signaling (56).
As noted above, the present results for EGFR-PI3K survival sig-
naling stand in some contrast to reports of EGFR and other sig-
nals to ERK1/2 to promote cell survival under other circumstances 
(51). In particular, respiratory syncytial virus may trigger EGFR 
and ERK1/2 activation (and IL-8 release) in cultured epithelial 
cells during the acute infection, but these studies were performed 
using transformed (A549) cells with necessarily altered death 
pathways or in submerged cell cultures that do not differentiate 
into ciliated epithelial cells (50). Nonetheless, acute infection with 
respiratory syncytial virus (as well as SeV and influenza virus) may 
promote epithelial cell survival in the acute setting based on che-
mokine-dependent activation of either PI3K/Akt or MEK/ERK sig-
naling both in vitro (using well-differentiated mouse and human 
cells) and in vivo (using a mouse model of acute infection) (38). 
In contrast to the situation for acute infection, the present find-
ings therefore highlight the change in epithelial survival signals in 
the chronic setting and are again remarkable for using high-fidel-
ity models in vitro and in vivo to establish that EGFR signals via 
PI3K/Akt selectively regulate ciliated cell survival.
The selective effect of PI3K but not MEK1/2 inhibition in the 
present system may also indicate that there is little contribution 
from the interaction of downstream signaling pathway through 
positive- or negative-feedback mechanisms. There is, however, sig-
nificant overlap between EGFR- and IL-13–signaling events despite 
distinct outcomes. EGFR activation of a PI3K/Akt signal is directed 
at preventing apoptosis, whereas IL-13 signaling to PI3K as well 
as ERK1/2 and Stat6 are all directed toward increasing CLCA and 
MUC gene expression to promote goblet cell formation (ref. 5 and 
A.C. Patel, J.D. Morton, and M.J. Holtzman, unpublished observa-
tions). The distinct outcomes of EGFR and IL-13 activation of PI3K 
and ERK1/2 are likely related to further diversity in downstream 
signaling. For example, EGFR survival signals may be mediated by 
Akt-dependent phosphorylation and inactivation of the proapop-
totic factor BAD whereas other downstream targets of Akt may con-
tribute to mucin gene expression (57, 58). The present results help 
to lay the biologic basis for defining these downstream events.
The present results complement previous results suggesting that 
Clara cells also give rise to mucous cells. Thus, allergen-induced gob-
let cell metaplasia is accompanied by morphologic and biochemical 
evidence of CCSP-positive Clara cells containing mucous granules 
in mice (22–24). Inhibitor effects were not reported in those studies, 
but at least 1 report showed a decrease in Clara cell level concomitant 
with an increase in goblet cell level consistent with Clara-to-goblet 
cell transdifferentiation (22). Similarly, others used the rat CCSP 
promoter to delete endogenous IL-13R signaling and downregu-
late mucous cell metaplasia in allergen-challenged mice (6). Given 
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derived from ciliated cells. However, comparison to the present results 
is complicated by the change in stimulus (from allergen to virus) and 
genetic background (from Balb/cJ to C57BL/6J). Moreover, IL-13 
may regulate CCSP expression (Y. You and S. Brody, unpublished 
observations, and ref. 25), and the rat CCSP promoter system may 
not be specific for mouse Clara cell expression. In fact, significant 
levels of CCSP-driven recombination can be found in ciliated airway 
epithelial cells (59). Thus, it may be necessary to track other markers 
of Clara cell lineage to fully define the relative contribution of Clara 
versus ciliated cell populations to goblet cell metaplasia. We found 
virus-induced decreases in Clara cell levels that were reversed by EGFR 
blockade but unchanged after IL-13 inhibition, so the significance 
of any Clara cell contribution to mucous cell metaplasia after viral 
infection remains uncertain. Nonetheless, the present observations 
of CCSP and β-tubulin colocalization with MUC5AC in mice and in 
humans suggests that ciliated and Clara cells may each demonstrate 
sufficient plasticity to contribute to mucous cell metaplasia.
Taken together, the present report extends the line of reasoning 
that airway epithelial cells may be specially programmed for normal 
immune defense (especially against respiratory viruses) and abnor-
mally programmed in airway disease. Previous work focused on 
other epithelial immune responses (notably interferon signaling) 
and how the epithelium clears infection in the short term (60, 61), 
whereas the present work focuses on EGFR and IL-13 and how the 
epithelium responds in the long term. Similar to other epithelial 
responses, the EGFR and IL-13 signals were likely developed to pro-
tect host epithelial cells from the lethal effect of viruses and to opti-
mize mucosal immunity. As noted above (Figure 10), the epithelial 
EGFR antiapoptotic system may protect the host cell (often the cili-
ated cell) from cytopathic effects that allow spread of infection. In 
parallel, the IL-13 goblet cell system may direct increases in mucus 
formation to aid mucociliary clearance of cellular and microbial 
debris from the airway. Both of these strategies are likely achieved 
in concert with epithelial interferon signaling that also protects the 
host cell by inhibiting viral replication. The present work adds the 
critical piece that demonstrates how, in some genetic settings, this 
normally protective response may be skewed toward a persistent 
response that results in a chronic asthma/bronchitis phenotype. 
Further study is needed to determine whether this genetic suscep-
tibility is linked to EGFR mutations that confer antiapoptotic sig-
nals and inhibitor sensitivity in lung cancer cells (62) or whether 
persistent EGFR activation is connected to IFN signaling and 
chronic Stat1 activation found in asthma (63), as may be the case in 
other epithelial barriers (64). Nonetheless, the present results dem-
onstrate that the abnormality in epithelial immune-response pro-
gramming can be corrected by targeted inhibition of critical signal-
ing steps. Treatment with EGFR tyrosine kinase inhibitors allows 
for the ciliated cells to proceed toward programmed cell death in a 
manner that appears analogous to virus-inducible apoptosis while 
IL-13 blockade appears to prevent the transition from ciliated 
to goblet cells. This new scheme thereby indicates that epithelial 
remodeling toward an asthma/bronchitis phenotype depends on 
both EGFR survival and IL-13 transdifferentiation signals such 
that treatment to block both of these signals would be required to 
fully restore the airway epithelium to its original architecture.
.FUIPET
Mice and viral inoculation. C57BL/6J and Balb/cJ mice were obtained from 
Jackson Laboratory at 5 weeks of age and were maintained for study at 6–7 
weeks of age as described previously (36–38) under protocols approved by 
the Washington University Animal Studies Committee. SeV was grown in 
embryonated hen eggs and harvested to provide a viral stock solution such 
that 5000 EID50 (50% egg infectious dose) was equivalent to 2 × 105 PFUs. 
This inoculum or an equivalent amount of UV-inactivated SeV was deliv-
ered intranasally in 30 μl PBS under ketamine/xylazine anesthesia. Under 
these conditions, viral tissue levels are maximal at 3–5 days after inocula-
tion, and viral clearance is complete by day 12 (36–38). Sentinel mice and 
experimental control mice were handled identically to inoculated mice 
and exhibited no serologic or histologic evidence of exposure to 11 rodent 
pathogens (including SeV). For EGFR blockade, mice were treated with 
EKB-569 (obtained from L.M. Greenberger, Wyeth Pharmaceuticals, Pearl 
River, New York, USA; 20 mg/kg in pH 2.0 water given by gavage) or vehicle 
control given daily for postinfection days 10–21. For IL-13 blockade, mice 
were given subcutaneous injections of sIL-13Rα2-Fc (obtained from D.D. 
Donaldson, Wyeth Ayerst, Cambridge, Massachusetts, USA; 200 μg/mouse 
in PBS) or control Fc at 12, 14, 17, and 20 days after inoculation.
Histochemistry. Mouse lung was fixed by intratracheal instillation of 4% 
paraformaldehyde at 25-cm H2O pressure, embedded in paraffin, and cut into 
3-μm thick sections for H&E or immunostaining. For immunostaining, tissue 
sections were deparaffinized, rehydrated in graded alcohol, and encircled with 
a hydrophobic film (ImmEdge PEN; Vector Laboratories). For antigen retriev-
al, sections were digested with proteinase K (Sigma-Aldrich) at a final con-
centration of 40 μg/ml in PBS for 5 minutes and then treated in 3% hydrogen 
peroxide in distilled water for 10 minutes to quench endogenous peroxidase 
activity. Nonspecific protein binding was blocked with 3% BSA and 2% goat 
serum in Tris-buffered saline (pH 8.0) with 0.2% Tween 20 (TBST) for 1 hour. 
Primary antibodies were diluted in blocking buffer and incubated overnight 
at 4°C at a final concentration of 0.05 or 0.1 μg/ml for human and mouse tis-
sue sections, respectively. EGFR was detected using rabbit anti-human EGFR 
antibody SC-03 (Santa Cruz Biotechnology Inc.) directed against amino 
acid residues 1005–1016, which are identical to corresponding sequences in 
murine EGFR. Phosphorylated EGFR (p-EGFR) was detected using rabbit 
anti–p-EGFR (Tyr845) antibody 2231 (Cell Signaling Technology) directed 
against phosphorylated Tyr845. For this antibody, final concentrations of 0.16 
and 0.32 μg/ml were used for human and mouse tissues, respectively. Ciliated, 
Clara, and goblet cells were identified using mouse anti–β-tubulin IV mAb 
(Sigma-Aldrich), goat anti-CCSP antibody (Santa Cruz Biotechnology), and 
mouse anti-human MUC5AC mAb 45M1 (Lab Vision Corp.), respectively. 
To verify specificity, sections were also incubated with primary antibodies 
that were preabsorbed with 10-fold excess of peptide antigen or with nonim-
mune rabbit IgG (Santa Cruz). After primary antibody binding, sections were 
washed with TBST and then incubated with biotinylated goat anti-rabbit IgG 
(2 μg/ml). Signals were amplified with the Elite ABC method and 3,3′-diami-
nobenzidine chromogen according to the manufacturer’s protocols (Vector 
Laboratories). Sections were counterstained with hematoxylin, dehydrated, 
and mounted with Cytoseal 60 (Stephens Scientific).
Immunofluorescence was performed in the same manner as 
immunostaining for light microscopy except that tissues were frozen in Tis-
sue-Tek OCT (Sakura Finetek Co.), sections were blocked with 2% donkey 
serum (Jackson ImmunoResearch Laboratories Inc.), primary antibody bind-
ing was detected using CY-3– or FITC-conjugated antibodies (Jackson Immu-
noResearch Laboratories Inc.) for 30 minutes at 25°C, and sections were 
counterstained with Hoechst dye 33432 (Invitrogen Corp.). Sections were 
imaged with light or immunofluorescent microscopy (BX-51; Olympus) inter-
faced to a digital photomicrography system (CCD Camera and MagnaFire 
software, version 2; Optronix). Reporter was quantified by counting ciliated 
cells in pulmonary airways per mm of basement membrane with analysis per-
formed using the NIH Image program (http://rsb.info.nih.gov/nih-image), as 
described previously (36, 37, 63). Confocal microscopy was performed using a 
Zeiss laser scanning system with LSM-S10 software, version 3.2.
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Human tissue procurement and analysis. Asthmatic patients with and with-
out glucocorticoid treatment and healthy control subjects were recruited, 
characterized, and subjected to endobronchial biopsy as described previ-
ously (37, 63). Endobronchial biopsies were washed with PBS and incu-
bated with 10% neutral buffered formalin for 18 hours at 25°C followed 
by histochemistry as described above. In addition, we obtained lung tis-
sue samples from COPD patients who were undergoing lung resection or 
transplantation and processed them as described above. All human studies 
were approved by the Washington University Human Studies Committee, 
and all subjects gave informed consent.
Proliferation markers. For BrdU immunostaining, mice received BrdU 
(100 mg/kg) intraperitoneally at 48 hours, 24 hours, and 4 hours prior to 
euthanasia. BrdU was detected with an anti-BrdU staining kit (Zymed Labora-
tories Inc.) according to the manufacturer’s protocol. Ki67 immunostaining, 
was performed with anti-Ki67 Ab (Novocastra) using the same protocol as 
for EGFR immunostaining except for pretreatment of heat-induced antigen 
retrieval using Antigen Unmasking Solution (Vector Laboratories). PCNA 
staining was performed with biotinylated anti-mouse PCNA Ab (DakoCyto-
mation) using the ABC method (Vector Laboratories).
Airway epithelial cell culture and treatment. Primary air-liquid interface cultures 
of mTECs were established as described previously (53). Human airway epi-
thelial cell cultures were established from tracheobronchial specimens har-
vested from lung explants of COPD patients undergoing transplantation and 
from lung transplant donors without lung disease using the same culture 
conditions. In all cases, cells were grown in basic medium (DMEM/Ham’s 
F-12 with 30 mM HEPES, 4 mM L-glutamine, 3.5 mM NaHCO3, 0.01% Fun-
gizone, and penicillin/streptomycin) supplemented with 10 μg/ml insulin, 
10 μg/ml transferrin, 0.1 μg/ml cholera toxin, 25 ng/ml EGF (BD), 30 μg/ml 
bovine pituitary extract, and 5% FBS in the upper and lower compartments. 
After the cells developed transmembrane electrical resistance greater than 
1000 Ohm/cm2, the air-liquid interface condition was established by wash-
ing the membrane with PBS and changing the medium in the lower compart-
ment to basic medium supplemented with 2% NuSerum (BD Biosciences). 
For EGFR stimulation, cells were incubated in basic medium for 24 hours and 
then in basic medium containing EGF (1–100 ng/ml; Upstate Biotechnol-
ogy) added to the upper and/or lower compartments for 10 minutes at 37°C. 
EGFR signaling inhibitors or vehicle control (0.1 % DMSO) were added to the 
lower compartments on a daily basis for long-term experiments or for 1.5–6 
hours to the upper and lower compartments for short-term experiments. 
EGFR tyrosine kinase inhibitor PD153035, MEK1/2 inhibitor PD98059, 
EGFR tyrosine kinase inhibitor AG1478, and PI3K inhibitor LY294002 were 
from Calbiochem, and z-VAD-fmk was from Enzyme Systems Products. 
Recombinant human or mouse IL-13 from Preprotech was added to upper 
and lower compartments at 24 hours before air-liquid interface conditions 
and was maintained in the lower compartment throughout the experiment.
Western blotting. For whole lung analysis, the left lobe of mouse lung was 
homogenized in RIPA buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% 
SDS in PBS) containing phosphatase inhibitor cocktail (Sigma-Aldrich). Tra-
cheal tissue and mTECs were collected in cell lysis buffer containing 20 mM 
Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton-X 100, 
1.0 μg/ml leupeptin, 10 μg/ml aprotinin, 0.2 mM phenylmethylsulfonyl 
fluoride, 1 mM sodium orthovanadate, 0.1 mM sodium fluoride, 2.5 mM 
sodium pyrophosphate, and 1 mM β–glycerophosphate. Cell lysates were 
cleared by centrifugation, and supernatant proteins were separated on 
4–15% gradient SDS-PAGE and transferred to PVDF membranes (Milli-
pore). The membranes were blotted against antibodies to EGFR, p-EGFR, 
p-ERK1/2, activated caspase-3, p-Stat6 (Cell Signaling Technology), 
p-Akt (BD Biosciences), caspase-9 (Stressgen Biotechnologies), and β-actin 
(Chemicon International). Primary antibody binding was detected with 
secondary antibodies conjugated to horseradish peroxidase and enhanced 
chemiluminescence (Amersham Pharmacia Biotech).
Immunocytochemistry. Cultured cells were washed twice with PBS at 4°C, 
fixed in 4% paraformaldehyde for 10 minutes at 25°C, washed with PBS, 
and permeabilized with ethanol:acetic acid (2:1, vol/vol) for 5 minutes at 
–20°C for TUNEL reaction or with 0.2% Triton-X for 5 minutes at 25°C for 
immunostaining. Permeabilized cells were then washed with PBS and sub-
jected to the TUNEL reaction (Intergen Co.) or blocked with 2% fish gel for 
1 hour at 25°C and incubated with rabbit anti-active caspase-3 (BD Biosci-
ences), rabbit anti-EGFR (Santa Cruz Biotechnology Inc., rabbit anti–p-EGFR 
(Cell Signaling Technology), mouse anti-β-tubulin IV, or rabbit anti–γ-tubulin 
(Sigma-Aldrich) antibodies overnight at 4°C. Primary antibody binding was 
detected with goat anti-mouse or donkey anti-rabbit FITC or CY3 secondary 
antibody. Cells were counterstained with 4 μg/ml Hoescht 33258 (Invitrogen 
Corp.) to check nuclear morphology, and then imaged as described above.
Flow cytometry. mTECs were cultured as above and removed from Tran-
swell culture using cell dissociation solution (Sigma-Aldrich) containing 
0.25% trypsin and 0.1% EDTA. Cells were washed with HBSS containing 
0.2% BSA and incubated with 5 μg/ml JC-1 (Invitrogen Corp.) for 15 min-
utes at 25°C. Cells with mitochondrial membrane depolarization were 
detected by a shift from low to high emission in green fluorescence (FL1) 
using a FACSCalibur flow cytometer and CellQuest software (BD).
Electron microscopy. Cells on membranes were prepared for transmission 
electron microscopy (TEM) as previously described (53). In brief, samples 
were fixed with 2.5% glutaraldehyde and stained with 1.25% osmium 
tetroxide. Cells were counterstained with 2.0% tannic acid, blocked for sec-
tioning, and imaged on a Zeiss 902 model microscope.
Statistics. Values for histochemistry of mouse tissues were analyzed using 
a 1-way analysis of variance (ANOVA) for a factorial experimental design. 
If significance was achieved by 1-way analysis, post-ANOVA comparison 
of means was performed using Scheffe’s F test. P < 0.05 was considered 
statistically significant.
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